Vertex Initiates Phase 2 Medical Trial System for VX-548 for the Procedure of Acute Soreness

Evidence-of-concept analyze of VX-548 in acute ache adhering to bunionectomy surgical procedure open for enrollment –

Second Period 2 analyze of VX-548 in acute soreness next abdominoplasty operation to get started in the coming weeks –

BOSTON, July 19, 2021–(Enterprise WIRE)–Vertex Prescription drugs Integrated (Nasdaq: VRTX) these days announced that it has begun a Phase 2 evidence-of-strategy (POC) research in acute agony adhering to bunionectomy surgical treatment with the selective NaV1.8 inhibitor VX-548 and that it expects to start a next Period 2 study in acute discomfort subsequent abdominoplasty surgical treatment in the coming

Read more